Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk
Scott D. Neidich, Youyi Fong, Shuying S. Li, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 11, pp. 4838-4849
Open Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Peter B. Gilbert, David C. Montefiori, Adrian B. McDermott, et al.
Science (2022) Vol. 375, Iss. 6576, pp. 43-50
Open Access | Times Cited: 1020
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Barton F. Haynes, Kevin Wiehe, Persephone Borrow, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 3, pp. 142-158
Open Access | Times Cited: 206
Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals
Savannah E. Butler, Andrew R. Crowley, Harini Natarajan, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 115
Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA
Bowen Li, Allen Yujie Jiang, Idris Raji, et al.
Nature Biomedical Engineering (2023)
Closed Access | Times Cited: 68
Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity
Jennifer L. Yates, Dylan Ehrbar, Danielle Hunt, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 7, pp. 100329-100329
Open Access | Times Cited: 88
Current approaches to HIV vaccine development: a narrative review
Jiae Kim, Sandhya Vasan, Jérôme H. Kim, et al.
Journal of the International AIDS Society (2021) Vol. 24, Iss. S7
Open Access | Times Cited: 70
Improving random forest predictions in small datasets from two-phase sampling designs
Sunwoo Han, Brian D. Williamson, Youyi Fong
BMC Medical Informatics and Decision Making (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 61
Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals
Elizabeth Fraley, Cas LeMaster, Eric S. Geanes, et al.
BMC Medicine (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 59
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
C. Pierre, Lily E. Adams, Jaclyn S. Higgins, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 6, pp. e1011569-e1011569
Open Access | Times Cited: 11
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial
Glenda Gray, Kathryn Mngadi, Ludo Lavreys, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 11, pp. 1201-1212
Open Access | Times Cited: 8
Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge
Barbara K. Felber, Zhongyan Lu, Xintao Hu, et al.
Cell Reports (2020) Vol. 31, Iss. 6, pp. 107624-107624
Open Access | Times Cited: 52
Coming together at the hinges: Therapeutic prospects of IgG3
Thach H. Chu, Edward F. Patz, Margaret E. Ackerman
mAbs (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 50
Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine
Chau Quang, J. L. Anderson, Fiona M. Russell, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
When Therapeutic IgA Antibodies Might Come of Age
Delphine Sterlin, Guy Gorochov
Pharmacology (2020) Vol. 106, Iss. 1-2, pp. 9-19
Open Access | Times Cited: 41
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
Fatima Laher, Zoe Moodie, Kristen W. Cohen, et al.
PLoS Medicine (2020) Vol. 17, Iss. 2, pp. e1003038-e1003038
Open Access | Times Cited: 39
Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis
David A. Spencer, Benjamin S. Goldberg, Shilpi Pandey, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 23
Robust antibody and cellular responses induced by DNA-only vaccination for HIV
Stephen C. De Rosa, Srilatha Edupuganti, Yunda Huang, et al.
JCI Insight (2020) Vol. 5, Iss. 13
Open Access | Times Cited: 34
The kinetics of IgG subclasses and contributions to neutralizing activity against SARS‐CoV‐2 wild‐type strain and variants in healthy adults immunized with inactivated vaccine
Weixin Chen, Lichi Zhang, Juan Li, et al.
Immunology (2022) Vol. 167, Iss. 2, pp. 221-232
Open Access | Times Cited: 19
Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector functions magnitude but not durability
Zhanna Shubin, Sherry Stanfield-Oakley, Jiraporn Puangkaew, et al.
AIDS (2023)
Open Access | Times Cited: 11
Positive-unlabeled learning to infer protection status and identify correlates in vaccine efficacy field trials
Shiwei Xu, Natasha S. Kelkar, Margaret E. Ackerman
iScience (2024) Vol. 27, Iss. 3, pp. 109086-109086
Open Access | Times Cited: 3
New technologies in therapeutic antibody development: The next frontier for treating infectious diseases
Sheila M. Keating, Brett W. Higgins
Antiviral Research (2024) Vol. 227, pp. 105902-105902
Closed Access | Times Cited: 3
Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41
Maxence Duchemin, Daniela Tudor, Andréa Cottignies-Calamarte, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 28
Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk
Erica Andersen‐Nissen, Andrew Fioré-Gartland, Lamar Ballweber-Fleming, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 3, pp. e1009363-e1009363
Open Access | Times Cited: 25
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial
Shuying S. Li, Peter B. Gilbert, Lindsay N. Carpp, et al.
Journal of Virology (2019) Vol. 93, Iss. 21
Open Access | Times Cited: 27
Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape
Cathrine Scheepers, Valerie Bekker, Colin Anthony, et al.
Cell Reports (2020) Vol. 33, Iss. 8, pp. 108430-108430
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top